Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ. Khera T, et al. Among authors: vercauteren k. Antiviral Res. 2017 Mar;139:129-137. doi: 10.1016/j.antiviral.2017.01.001. Epub 2017 Jan 3. Antiviral Res. 2017. PMID: 28062191 Free PMC article.
Griffithsin has antiviral activity against hepatitis C virus.
Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J. Meuleman P, et al. Among authors: vercauteren k. Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67. doi: 10.1128/AAC.00633-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896910 Free PMC article.
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Vercauteren K, et al. Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30. Hepatology. 2014. PMID: 24797654 Free PMC article.
HCV animal models and liver disease.
Vercauteren K, de Jong YP, Meuleman P. Vercauteren K, et al. J Hepatol. 2014 Nov;61(1 Suppl):S26-33. doi: 10.1016/j.jhep.2014.07.013. Epub 2014 Nov 3. J Hepatol. 2014. PMID: 25443343 Free article. Review.
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF. Mailly L, et al. Among authors: vercauteren k. Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23. Nat Biotechnol. 2015. PMID: 25798937 Free PMC article.
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, von Schaewen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FW, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T. Perin PM, et al. Among authors: vercauteren k. Hepatology. 2016 Jan;63(1):49-62. doi: 10.1002/hep.28111. Epub 2015 Oct 9. Hepatology. 2016. PMID: 26248546 Free PMC article.
Animal models for the study of HCV.
Vercauteren K, de Jong YP, Meuleman P. Vercauteren K, et al. Curr Opin Virol. 2015 Aug;13:67-74. doi: 10.1016/j.coviro.2015.04.009. Epub 2015 May 23. Curr Opin Virol. 2015. PMID: 26304554 Free PMC article. Review.
179 results